Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Elderly (age 70 years or older) or >18 years old AND poor risk (ECOG 2) newly diagnosed stage
IIIA-C (AJCC 8th edition) inoperable non-small cell lung cancer (NSCLC) patients are eligible
to participate in this phase II open label study of concurrent, split course chemoradiation
followed by Durvalumab (MEDI4736).